A New Therapeutic Approach in Non-Specific Vaginitis

Boos, R.; Rüttgers, H.

doi:10.1159/000269919

Cited by 3 publications

(3 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in the placebo group a total of 125 separate reinfec tions had to be treated, while in the immu nized group only 67 new infections ap peared. These figures, as far as they can in fact be compared with the earlier studies of Harris [9], Litschgi [14] and Verling [24] and in view of the differences in methodology, confirm the positive experience with this immunization therapy made earlier by these authors and by ourselves [4], It has to be borne in mind that the partners of the treated women were not investigated as to whether they had any transmissible infec tion, such as G. vaginalis, or not. Furthermore, as we had no information on sexual promis cuity, only speculation could be made on the risk of these women becoming re-infected by sexual contact.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Bacterial Vaginitis: Protection against Infection and Secretory Immunoglobulin Levels in the Vagina after Immunization Therapy with Gynatren®

Rüttgers

1988

Gynecol Obstet Invest

Self Cite

View full text Add to dashboard Cite

In a prospective, randomized double-blind study the prophylactic effect of the immunotherapeutic agent, Gynatren®, against reinfection was investigated in 192 patients with bacterial vaginitis (95 treated with the active preparation versus 97 with placebo). In 30 and 25% of the patients in the two groups, respectively, it was the third or even more frequent infection in a period of 12 months. In a further 46 and 39%, respectively, it was the second infection in the course of a year. All the patients were given local treatment with tetracycline-amphotericin B vaginal suppositories and at the same time vaccinated with Gynatren or placebo. One month after the start of treatment, 85% of the patients in the active-treatment group and 83% in the placebo group were asymptomatic and free from pathogenic bacteria. After 3 months 78% in the active-treatment group and 60% in the placebo group were free from infection. After 6 months 76 and 40%, and after 12 months 75 and 37% of the women in the active-treatment and placebo groups, respectively, were free from clinical symptoms and pathogenic bacteria. These results correlated with the concentrations of local antibodies (secretory immunoglobulin) detectable in the vaginal secretion.

show abstract

Section: Discussionsupporting

confidence: 77%

“…The vaginal pH value was determined, with the aid of a speculum, by means of a pH electrode in the middle third of the vagina [4], For disinfection, the electrode was immersed in 70% ethanol. Calibration was performed immediately before using the elec trode, always with fresh buffer.…”

Section: Methodsmentioning

confidence: 99%

Bacterial Vaginitis: Protection against Infection and Secretory Immunoglobulin Levels in the Vagina after Immunization Therapy with Gynatren®

Rüttgers

1988

Gynecol Obstet Invest

Self Cite

View full text Add to dashboard Cite

show abstract

“…Boos and Riittgers [7], studying 182 patients with non-specific vaginitis, reported relief from symptoms in 162 patients (89%) 4 weeks after the com pletion of the immunization regimen. Harris [8] reported that 95% of his patients with vaginitis (86 out of 90) became free of symptoms 4 weeks after the administration of the 3rd of 3 injections; these results were obtained in a patient population suffering mainly from Gardnerella vaginitis.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Chronic Colpo-Vaginitis by Stimulation of the Immune System

Verling¹

1984

Gynäkol Geburtshilfliche Rundsch

View full text Add to dashboard Cite

We evaluated 100 patients with chronic colpo-vaginitis treated with the immunotherapeutic Gynatren/SolcoTrichovac. 44 patients suffered from ‘non-specific’ vaginitis, 42 were infected with Candida albicans and 14 with Chlamydia vaginalis. All patients had had several episodes of vaginal infections, some of them over several years, and 53 patients had current infection which, despite treatment with various drugs and remedies, had already persisted more than 2 months. The treatment consisted of 3 intramuscular injections at intervals of 2 weeks. Four weeks after beginning treatment all patients were free from pain despite the fact that the immune response was not yet fully developed. Four weeks later 72 % were classified as cured or much improved and 6 months after beginning therapy 49 of the 89 patients examined at this time were cured and a further 11 patients presented with only ‘mild symptoms’.

show abstract